p16 Hypermethylation in the early stage of hepatitis B virus-associated hepatocarcinogenesis

Cancer Letters

Volumn 190, Issue 2, 2003, Pages 213-219

  Shim, Yhong Hee ^a   Yoon, Ghil Suk ^b   Choi, Hae Jung ^b   Chung, Young Hwa ^b   Yu, Eunsil ^b  

^a Konkuk University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

Author keywords

Cirrhotic nodule; Dysplastic nodule; Early hepatocellular carcinoma; Hepatitis B virus infection; Multistep carcinogenesis; p16 hypermethylation

Indexed keywords

PARAFFIN; PROTEIN P16;

ARTICLE; CANCER SUSCEPTIBILITY; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DNA METHYLATION; DYSPLASIA; EARLY CANCER; GENE FREQUENCY; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; PRIORITY JOURNAL; TISSUE SECTION;

HEPATITIS B VIRUS;

EID: 0037455979     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(02)00613-4     Document Type: Article

References (38)

1. Hytiroglou P., Theise N.D., Schwartz M., Mor E., Miller C., Thung S.N. Macroregenerative nodules in a series of adult cirrhotic liver explants: Issues of classification and nomenclature. Hepatology. 21:1995;703-708.
2. Theise N.D. Macroregenerative (dysplastic) nodules and hepatocarcinogenesis: theoretical and clinical considerations. Semin. Liver Dis. 15:1995;360-371.
3. Terminology of nodular hepatocellular lesions. Hepatology. 22:1995;983-993.
4. Hytiroglou P., Theise N.D. Differential diagnosis of hepatocellular nodular lesions. Semin. Diagn. Pathol. 15:1998;285-299.
5. Wakasa K., Haba T., Hamada T., Sasaki M., Sakurai M. Early hepatocellular carcinoma macroscopically resembling adenomatous hyperplasia: pathological resemblance to carcinoma-in-situ. Pathol. Int. 47:1997;54-59.
6. Sakamoto M., Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn. J. Clin. Oncol. 28:1998;604-608.
7. Hui A.M. Molecular basis of multistep hepatocarcinogenesis: genetic and epigenetic event. Scand. J. Gastroenterol. 8:1999;738-742.
8. Robinson W.S. Molecular events in the pathogenesis of hepadna virus-associated hepatocellular carcinoma. Annu. Rev. Med. 45:1994;297-323.
9. Murakami Y., Hayashi K., Hirohashi S., Sekiya T. Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. Cancer Res. 51:1991;5520-5525.
10. Nagai H., Pineau P., Tiollais P., Buendia M.A., Dejean A. Comprehensive allelotyping of human hepatocellular carcinoma. Oncogene. 14:1997;2927-2933.
11. Piao Z., Park C., Park J.H., Kim H. Allelotype analysis of hepatocellular carcinoma. Int. J. Cancer. 75:1998;29-33.
12. Kanai Y., Ushijima S., Tsuda H., Sakamoto S. Aberrant DNA methylation precedes loss of heterozygosity on chromosome 16 in chronic hepatitis and liver cirrhosis. Cancer Lett. 148:2000;73-80.
13. Kondo Y., Kanai Y., Skamoto M., Mizokame M., Ueda R., Hirohashi S. Gene instability and aberrant DNA methylation in chronic hepatitis and cirrhosis - a comprehensive study of loss of heterozygosity and microsatellite instability at 39 loci and DNA hypermethylation on 8 CpG islands in microdissected specimens from patients with hepatocellular carcinoma. Hepatology. 32:2000;970-979.
14. Oda T., Tsuda H., Sakamoto M., Hiroshi S. Different mutations of the p53 gene in nodule-in-nodule hepatocellular carcinoma as an evidence for multistage progression. Cancer Lett. 83:1994;197-200.
15. Yamashita A. Comparison of the proliferative capacity of adenomatous hyperplasia and well differentiated hepatocellular carcinoma. J. Gastroenterol. 31:1996;373-378.
16. Miura N., Horikawa I., Nishimoto A., Ohmura H., Ito H., Hirohashi S., Shay J.W., Oshimura M. Progressive telomere shortening and telomerase reactivation during hepatocellular carcinogenesis. Cancer Genet. Cytogenet. 93:1997;56-62.
17. Kang Y.K., Kim C.J., Kim W.H., Kim H.O., Kang G.H., Kim Y.I. p53 mutation and overexpression in hepatocellular carcinoma and dysplastic nodules in the liver. Virchows Arch. 432:1998;27-32.
18. Hunter T., Pines J. Cyclins and cancer II: cyclin D and CDK inhibitors come of age. Cell. 79:1994;573-582.
19. Sherr C.J. Cancer cell cycles. Science. 274:1996;1672-1677.
20. INK4a. Exp. Cell Res. 237:1997;7-13.
21. Liggett W.H., Sidransky D. Role of the p16 tumor suppressor gene in cancer. J. Clin. Oncol. 16:1998;1197-1206.
22. Sugimura T., Ushijima T. Genetic and epigenetic alterations in carcinogenesis. Mutat. Res. 462:2000;235-246.
23. INK4 in hepatocellular carcinoma. Hepatology. 24:1996;575-579.
24. Biden K., Young J., Buttenshaw R., Searle J., Cooksley G., Xu D.B., Leggett B. Frequency of mutation and deletion of the tumor suppressor gene CDKN2A (MTS1/p16) in hepatocellular carcinoma from an Australian population. Hepatology. 25:1997;593-597.
25. INK4(MTS1) gene occurs in a subset of patients with hepatocellular carcinoma. Hepatology. 25:1997;1376-1381.
26. Shen L., Fang J., Qiu D., Zgang T., Yang J., Chen D.S., Xiao S. Correlation between DNA methylation and pathological changes in human hepatocellular carcinoma. Hepato-Gastroenterology. 45:1998;1753-1759.
27. INK4A gene alterations in hepatocellular carcinoma. Oncogene. 18:1999;789-795.
28. Matsuda Y., Ichida T., Matsuzawa J., Sugimura K., Asakura H. p16INK4 is inactivated by extensive CpG methylation in human hepatocellular carcinoma. Gastroenterology. 116:1999;394-400.
29. Baek M.J., Piao Z., Kim N.-G., Park C., Shin E.C., Park J.H., Jung H.J., Kim C.G., Kim H. p16 is a major inactivation target in hepatocellular carcinoma. Cancer. 89:2000;60-68.
30. Okabe H., Satoh S., Kato T., Kitahara O., Yanagawa R., Yamaoka Y., Tsunoda T., Furukawa Y., Nakamura Y. Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of gene involved in viral carcinogenesis and tumor progression. Cancer Res. 61:2001;2129-2137.
31. Sells M.A., Chen M.L., Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. USA. 84:1987;1005-1009.
32. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., Baylin S.B. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc. Natl. Acad. Sci. USA. 93:1996;9821-9826.
33. INK4A gene promoter in chronic hepatitis and cirrhosis associated with hepatitis B or C virus. Gut. 48:2001;372-377.
34. Shim Y.H., Kang G.H., Ro J.Y. Correlation of p16 hypermethylation with p16 protein loss in sporadic gastric carcinomas. Lab. Invest. 80:2000;689-695.
35. Heller H., Kammer C., Wilgenbus P., Doerfler W. Chromosomal insertion of foreign (adenovirus typer 12, plasmid, or bacteriophage λ) DNA is associated with enhanced methylation of cellular DNA segments. Proc. Natl. Acad. Sci. USA. 92:1995;5515-5519.
36. Remus R., Kammer C., Heller H., Schmitz B., Schell G., Doerfler W. Insertion of foreign DNA into an established mammalian genome can alter the methylation of cellular DNA sequences. J. Virol. 73:1999;1010-1022.
37. Lu S.N., Lin T.M., Chen C.J. A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer. 62:1988;2051-2055.
38. Myohanen S.K., Baylin S.B., Herman J.G. Hypermethylation can selectively silence individual p16INK4A alleles in neoplasia. Cancer Res. 58:1998;591-593.